Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Big Is The Stomach Cancer Market Today And What Is Its Future Size?

The market size for stomach cancer has experienced a swift expansion in the past few years. A progression from $3.27 billion in 2024 to an anticipated $3.74 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.1%, has been forecasted. The historical growth can be traced back to factors such as the escalating prevalence of Helicobacter pylori infection, advancements in targeted therapies, increased adoption of combination chemotherapy treatments, surge in accessibility to immunotherapy procedures, and significant changes in lifestyle habits.

The market size for stomach cancer is projected to witness substantial growth in the forthcoming years. Predicted to rocket to $6.28 billion by 2029, this represents a compound annual growth rate (CAGR) of 13.9%. The pronounced growth during the forecast period is due to various factors, including escalated global instances of stomach cancer, a surge in both public and private healthcare investments, growing approval of targeted therapies and biologics, heightened interest of pharmaceutical companies in oncology, and increased collaborations between research institutions and biotech corporations. Factors defining the trends in the forecast period encompass incorporation of companion diagnostics, fusion of genomic testing in clinical practice, advancements in immunotherapy combinations, evolution in endoscopic techniques, and the progression of therapies based on microbiomes.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp

Which Key Factors Are Fueling Growth In The Stomach Cancer Market?

The growing occurrence of Helicobacter pylori infection is projected to stimulate the expansion of the stomach cancer market in the future. The ailment caused by the bacteria, Helicobacter pylori, that invades the stomach lining, leading to inflammation, ulcers and a heightened risk of stomach cancer, is what is referred to as Helicobacter pylori infection. The increasing occurrence of the infection can be attributed to inadequate sanitation that supports the transmission of the bacteria via fecal-oral and oral-oral routes in congested or unsanitary habitats. The Helicobacter pylori infection contributes to stomach cancer by inducing chronic inflammation and cellular harm in the stomach lining, resulting in preliminary changes that can lead to tumor formation. For instance, the Government of Canada, a government agency based in Canada, indicated that in November 2024, the recurrence rate of the infection was 19% in 2023. This rate, however, fluctuates based on factors like geographic location and age group. Thus, the escalating prevalence of the infection is fueling the growth of the stomach cancer market.

How Is The Stomach Cancer Market Segmented Across Key Categories?

The stomach cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

3) By Route of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Adenocarcinoma: Intestinal Type, Diffuse Type

2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma

3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors

4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid

5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

What Key Trends Are Driving Growth In The Stomach Cancer Market?

Leading businesses in the gastric cancer treatment market are prioritizing the creation of high-tech solutions, such as claudin (CLDN18.2)-based cytolytic antibody treatment, to heighten precision in primary therapies for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. This treatment employs a monoclonal antibody engineered to selectively bind to CLDN18.2-expressing tumor cells and initiate cytotoxic effects when integrated with chemotherapy, enhancing both progression-free and overall survival outcomes. For example, in October 2024, Japanese pharmaceutical firm Astellas Pharma US, Inc., introduced Vyloy, a CLDN18.2-focused cytolytic antibody for the treatment of gastric and GEJ cancers. This cutting-edge biologic treatment is given intravenously alongside fluoropyrimidine and platinum-based chemotherapy, providing a median progression-free survival advantage of up to 10.6 months and an overall survival of up to 18.2 months in clinical trials. By selectively targeting CLDN18.2-positive cancer cells, this treatment minimizes off-target toxicity and heightens treatment specificity— a notable advancement in personalized cancer therapy for advanced gastric cancer.

Who Are The Leading Companies Driving The Stomach Cancer Market?

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis Ag, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Eli Lilly And Company, Amgen Inc, Mayo Clinic, Daiichi Sankyo Company Limited., Illumina Inc., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited., Guardant Health Inc., Zai Lab Limited., MacroGenics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Which Region Dominates The Stomach Cancer Market Today?

North America was the largest region in the stomach cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25913&type=smp

Browse Through More Reports Similar to the Global Stomach Cancer Market 2025, By The Business Research Company

Tumor Ablation Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/tumor-ablation-global-market-report

Gastric Ulcers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-ulcers-global-market-report

Cancer Cachexia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model